Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2012

View Archived Issues

Bayer Yakuhin seeks additional approval for Fosrenol chewable tablets and granules in Japan

Adalimumab evaluated as a treatment for hidradenitis suppurativa in phase II trial

Brimonidine improves erythema in patients with rosacea

Novel IGF-I receptor inhibitors synthesized by Novartis and IRM

Chinese researchers present novel agents for cancer and other disorders

Roche discloses novel antibodies for cancer

Team in Israel patents new genetically modified muscle cells

Researchers at VaxInnate prepare novel dengue vaccines

Ablynx reports promising interim results from phase I/II ALX-0061 study

EYEGUARD-C gevokizumab study enters patient enrollment stage

Xilonix receives FDA fast track designation

Roche divulges new monovalent antigen-binding proteins

ADHD transdermal therapeutic enters phase II study

Shionogi-ViiV Healthcare completes initial registration package for dolutegravir

Combination of belinostat and doxorubicin shows efficacy against soft tissue sarcoma

Sarepta reports promising results from extension study of eteplirsen

Therapy targeting tumor antigens and immune tolerance evaluated in phase I study

VentiRx and Celgene form worldwide collaboration for VTX-2337

Combination therapy proves useful against head and neck cancer

HyperAcute Lung advances to phase IIb/III trial

ITCA-650 evaluated in phase II dose-finding study

EMA determines Sufentanil NanoTab PCA System eligible for centralized review

Tesaro obtains IND clearance to conduct phase I/II study of TSR-011

Pfizer reports topline results from phase III Prevenar 13 trial

OncoMed Pharmaceuticals advances two Notch pathway product candidates

FDA approves Cystaran for corneal cystine crystals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...